Oppenheimer & Co. Inc. bought a new position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 4,178 shares of the biopharmaceutical company’s stock, valued at approximately $508,000.

Several other hedge funds have also recently bought and sold shares of ALXN. BlackRock Inc. lifted its stake in Alexion Pharmaceuticals by 2,689.8% in the 1st quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock valued at $2,258,467,000 after buying an additional 17,960,356 shares in the last quarter. Vanguard Group Inc. lifted its stake in Alexion Pharmaceuticals by 3.1% in the 1st quarter. Vanguard Group Inc. now owns 14,467,456 shares of the biopharmaceutical company’s stock valued at $1,754,034,000 after buying an additional 433,293 shares in the last quarter. State Street Corp lifted its stake in Alexion Pharmaceuticals by 6.8% in the 1st quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock valued at $1,369,846,000 after buying an additional 718,756 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in Alexion Pharmaceuticals by 8.0% in the 1st quarter. Ameriprise Financial Inc. now owns 6,149,572 shares of the biopharmaceutical company’s stock valued at $745,579,000 after buying an additional 454,069 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Alexion Pharmaceuticals by 2.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 3,349,821 shares of the biopharmaceutical company’s stock valued at $407,573,000 after buying an additional 64,800 shares in the last quarter. 94.26% of the stock is currently owned by institutional investors and hedge funds.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 835 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the transaction, the director now owns 5,480 shares of the company’s stock, valued at $799,038.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Ann M. Veneman sold 700 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the transaction, the director now directly owns 6,315 shares in the company, valued at approximately $869,828.10. The disclosure for this sale can be found here. Insiders have sold 17,070 shares of company stock worth $2,416,869 in the last three months. Insiders own 4.35% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Oppenheimer & Co. Inc. Invests $508,000 in Alexion Pharmaceuticals, Inc. (ALXN)” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/15/oppenheimer-co-inc-invests-508000-in-alexion-pharmaceuticals-inc-alxn.html.

A number of research analysts recently weighed in on ALXN shares. Barclays PLC reaffirmed an “overweight” rating and issued a $155.00 price target on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. UBS AG reaffirmed a “buy” rating and issued a $142.00 price target (up from $140.00) on shares of Alexion Pharmaceuticals in a research note on Monday, June 26th. Deutsche Bank AG decreased their price target on shares of Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Thursday, May 25th. Morgan Stanley reaffirmed an “overweight” rating and issued a $153.00 price target (up from $141.00) on shares of Alexion Pharmaceuticals in a research note on Friday, July 28th. Finally, J P Morgan Chase & Co raised shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the company from $163.00 to $175.00 in a research note on Tuesday, September 5th. Five research analysts have rated the stock with a hold rating, twenty have issued a buy rating and three have issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $157.74.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 144.62 on Friday. The stock’s 50 day moving average is $138.46 and its 200-day moving average is $124.64. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34. The firm has a market cap of $32.28 billion, a P/E ratio of 62.71 and a beta of 1.40.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.48. The business had revenue of $912.00 million for the quarter, compared to the consensus estimate of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The company’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.13 earnings per share. Analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.61 EPS for the current fiscal year.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.